US Stock MarketDetailed Quotes

SGMT Sagimet Biosciences

Watchlist
  • 3.990
  • -0.060-1.48%
Close Mar 21 16:00 ET
  • 3.990
  • 0.0000.00%
Post 20:01 ET
128.46MMarket Cap-2.75P/E (TTM)

About Sagimet Biosciences Company

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Company Profile

SymbolSGMT
Company NameSagimet Biosciences
Listing DateJul 14, 2023
Issue Price16.00
Founded2006
CEOMr. David Happel
MarketNASDAQ
Employees14
Fiscal Year Ends12-31
Address155 Bovet Road,Suite 303
CitySan Mateo
ProvinceCalifornia
CountryUnited States of America
Zip Code94402
Phone1-650-561-8600
Websitehttp://www.sagimet.com

Company Executives

  • Name
  • Position
  • Salary
  • David Happel
  • President, Chief Executive Officer and Director
  • 2.69M
  • Elizabeth Rozek
  • General Counsel and Chief Compliance Officer
  • --
  • Dr. Eduardo Bruno Martins, D.Phil.,M.D.
  • Chief Medical Officer
  • 1.51M
  • Thierry Chauche
  • Chief Financial Officer and Principal Accounting Officer
  • --
  • George Kemble, PhD
  • Executive Chairman of the Board
  • 930.22K
  • Dr. Merdad V. Parsey, M.D.,PhD
  • Independent Director
  • 41.50K
  • Timothy P. Walbert
  • Independent Director
  • --
  • Dr. Beth C. Seidenberg,M.D.
  • Independent Director
  • 14.38K
  • Jennifer Ann Jarrett
  • Independent Director
  • --
  • Elizabeth Grammer
  • Independent Director
  • 43.00K
  • Dr. Anne M. Phillips, M.D.
  • Independent Director
  • --

Market Insights

Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

No. Symbol Price
Tesla
TSLA
248.710
Apple
AAPL
218.270
Meta Platforms
META
596.250
4
Microsoft
MSFT
391.260
5
Petroleo Brasileiro SA Petrobras
PBR
14.160
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
FOMC Press Conference, March 19, 2025
Monetary Policy: Navigating the Fed's Rate Cut Cycle
Changing Fed policy is altering the market math for investors.